Shares of Sophiris Bio Inc. (NASDAQ:SPHS) fell 3.4% on Monday . The company traded as low as $5.10 and last traded at $5.19, with a volume of 857,638 shares. The stock had previously closed at $5.37.

A number of brokerages have weighed in on SPHS. Echelon Wealth Partners reissued a “buy” rating and set a $5.00 target price on shares of Sophiris Bio in a report on Friday, June 10th. Maxim Group reissued a “buy” rating and set a $4.00 target price on shares of Sophiris Bio in a report on Friday, June 10th.

The firm has a 50 day moving average price of $3.35 and a 200-day moving average price of $1.99. The stock’s market cap is $107.20 million.

Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06. Equities analysts expect that Sophiris Bio Inc. will post ($0.73) earnings per share for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.